Midodrine Substipharm (Midodrine Hydrochloride)

Midodrine, the active ingredient in Midodrine Substipharm, is an alpha‑1 adrenergic agonist presented as an oral tablet for oral use. It is employed to raise blood pressure in patients with orthostatic hypotension, helping to reduce dizziness and fainting episodes. It is indicated for individuals who experience a significant drop in blood pressure upon standing, a condition that can impair daily activities.

GNH USA supplies Midodrine Substipharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured product handling and regulatory conformity across global markets.

Midodrine acts on the peripheral vascular adrenergic system to treat conditions characterized by low blood pressure.

Orthostatic hypotension: improves standing blood pressure and reduces dizziness. Neurogenic orthostatic hypotension: helps maintain vascular tone in autonomic failure. Syncope associated with orthostatic hypotension: lowers the frequency of fainting episodes.

Midodrine may cause a range of adverse reactions.

Common Side Effects: - Piloerection (goose‑bumps) - Pruritus (itching) - Urinary retention - Supine hypertension - Headache - Nausea

Serious or Rare Side Effects: - Severe hypertension, especially when lying down - Bradycardia - Allergic reactions such as rash or angioedema - Cardiac arrhythmias - Ischemic events in patients with underlying vascular disease

When prescribing Midodrine, several safety considerations are recommended.

Monitor blood pressure: check supine and standing values regularly. Avoid use in severe cardiac disease: risk of excessive hypertension. Caution in renal impairment: dose adjustment may be needed. Do not combine with other vasopressors without supervision. Store at ambient temperature: keep in the original container, protect from moisture and light.

Midodrine can interact with several drug classes, requiring attention to avoid adverse effects.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other α1‑adrenergic agonists: additive pressor effect. - Tricyclic antidepressants: may enhance pressor response.

Moderate Interactions (Monitor Closely): - Diuretics: may affect intravascular volume and blood pressure. - Beta‑blockers: may blunt compensatory tachycardia. - Anticholinergics: may increase urinary retention.